Gland Pharma reported a solid Q2 FY26, with consolidated revenue increasing 6% YoY to ₹1,486.9 Cr and profit (PAT) rising 12% YoY to ₹183.7 Cr.

The company's gross profit margin improved to 63%. Strong performance in the US market saw revenue grow 10% YoY to ₹827.9 Cr, while Europe also contributed with 16% YoY growth to ₹284.7 Cr.

Key growth drivers include a focus on complex injectables, with six products launched and three more awaiting approval.

The company is aggressively expanding its GLP-1/Pen/cartridge manufacturing capacity from ~40 million to 140 million units, exploring new opportunities.

Recent developments include seven new molecule launches in the USA and five ANDA approvals during the quarter.

Cenexi's operations, despite a planned shutdown, are progressing with infrastructure upgrades and key product ramp-ups.